PharmacogeneticsMyPGxNCT06660264
An Evaluation of the Impact of Pharmacist Personalized Medication Reviews With and Without a Discussion of Pharmacogenomic Results in an Employee Health Program.
A study testing Pharmacist Personalized Medication Review (PMR) and Discussion of Pharmacogenomic results during the PMR in people with Pharmacogenetics and Pharmacogenomic Drug Interaction, run by University of Pittsburgh at 1 site in United States.
Trial summary
The goal of this prospective randomized clinical trial is to learn if a pharmacist-provided personalized medication review (PMR) that discusses pharmacogenomic test results will improve medication outcomes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pharmacogenetics, Pharmacogenomic Drug Interaction
- What is being tested?
- Pharmacist Personalized Medication Review (PMR) and Discussion of Pharmacogenomic results during the PMR
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 600 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Jan 2025to 30 Jun 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- >/= 18 years old
- Enrolled in the UPMC insurance plan for at least 1 year
- Identified by UPMC Healthplan as a Pitt/UPMC employee who is likely to benefit from preemptive PGx panel testing based on polypharmacy, high annual prescription costs and a risk for poor medication-related outcomes based on exposure to medications with FDA or CPIC Level A/B PGx guidance using payer data
- Participating in Pitt+Me Discovery with elective return of PGx results
Who cannot join
- Previous panel PGx testing (self-reported)
- Have a terminal illness (specifically metastatic cancer, palliative care or hospice)
- Have had a liver, small bowel, or allogenic bone marrow/stem cell transplant
- Cannot provide informed consent and/or complete the study protocol due to serious cognitive impairment
- Institutionalized or too ill to participate (i.e. incarcerated, psychiatric or nursing home facility)
- Plan to drop UPMC Health Plan coverage for any reason within 12 months of enrollment
- Recent blood transfusion may be exclusionary only if the end of recruitment is nearing and there is insufficient time to observe a minimum waiting period between date of transfusion and date of sample collection. These minimum waiting periods are determined by type of transfusion: 7 days for platelets/plasma/cryoprecipitate; 2 months for packed red blood cells (PRBCs): and 6 months for whole blood or unknown type of transfusion. Although a transfusion is unlikely to have major effects on genotype results from a saliva sample, these time windows remove this concern.
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Pittsburgh
Pittsburgh, Pennsylvania, 15260
About this study
Official title: Implementing Risk-Based Preemptive Pharmacogenomic (PGx) Testing in Employee Health
The goal of this prospective randomized clinical trial is to learn if a pharmacist-provided personalized medication review (PMR) that discusses pharmacogenomic test results will improve medication outcomes.
The primary aim is to identify patients within the Pitt/UPMC employee health programs who are most likely to benefit from PGx testing based on prescription history. The second aim is to determine the effect of the pharmacist-provided PMR including PGx test results.
Participants 18 years of age and older who have undergone PGx testing through a independent biobanking study (Pitt+Me Discovery) will be randomly assigned to receive PMR with a discussion of PGx test results or PMR without PGx results. Those who receive PMR only will receive PGx results one year after their PMR. Researchers will compare the groups to see if a pharmacist-provided PMR using PGx test results will lead to better medication outcomes and lower medical costs.
- Conditions
- Pharmacogenetics, Pharmacogenomic Drug Interaction
- Being tested
- Pharmacist Personalized Medication Review (PMR), Discussion of Pharmacogenomic results during the PMR
- Keywords
- Precision Medicine, Medication Review, PGx, Pharmacist, Pharmacogenomics, Employee health
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pharmacist Personalized Medication Review (PMR)Other
Pharmacist-provided review of current medications and assessment of potential medication related problems.
Discussion of Pharmacogenomic results during the PMROther
Return of pharmacogenomic results and discussion of impact on medications.
| Study group | Role | What they receive |
|---|---|---|
| Immediate Return of Pharmacogenomic Results | Other | Participants will be randomized to immediate versus delayed return of pharmacogenomic results obtained from testing conducted by an independent biobanking study (Pitt+Me Discovery). Participants in the immediate group will receive a pharmacist Personalized Medication Review with PGx results. Receives: Other: Pharmacist Personalized Medication Review (PMR); Other: Discussion of Pharmacogenomic results during the PMR |
| Delayed Return of Pharmacogenomic Results | Other | Participants will be randomized to immediate versus delayed return of pharmacogenomic results obtained from testing conducted by an independent biobanking study. Participants in the delayed group with receive a pharmacist Personalized Medication Review without PGx results. The delayed group will receive results from the independent biobanking study (Pitt+Me Discovery) at 12 months after the Personalized Medication Review. Receives: Other: Pharmacist Personalized Medication Review (PMR) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Total Per Member Per Month (PMPM) Healthcare Costs
Change in participant total per member/per month (PMPM) healthcare costs using healthplan claims data from 12 months prior to the pharmacist Personalized Medication Review (PMR) visit to 12 months after the PMR visit.
Measured: From 12 Months prior to PMR visit and from the PMR visit to 12 Months after the PMR visit
Secondary outcomes (9)
Change in frequency of CPIC/FDA guideline concordant prescribing
Change in frequency of concordance of participant medication regimen with pharmacogenomics prescribing recommendations according to the Clinical Pharmacogenomics Implementation Consortium (CPIC) and U.S. Food \& Drug Administration (FDA) guidelines using electronic health record data.
Measured: Baseline, 12 Months after PMR visit
Change in healthcare utilization
Change in participant ER visits, hospitalizations, urgent care visits, specialist appointments, primary care appointments and unplanned care using UPMC Health Plan claims data from the year prior to the year after the pharmacist PMR visit.
Measured: From 12 Months prior to PMR visit and from the PMR visit to 12 Months after the PMR visit.
Number of adverse events as assessed using the Patient-Reported Outcome Measure, Inquiry into Side-Effects (PROMISE) survey
The Patient-Reported Outcome Measure, Inquiry into Side-Effects (PROMISE) allows participants to report common symptoms and suspected drug-related adverse events they may have experienced in the previous month. It includes a list of 22 common symptoms with option to write in other symptoms. For each symptom reported they are asked to indicate if they believe it might be a possible side effect of their medication. Scores range from 0 to 23. Higher scores indicate greater number of reported symptoms.
Measured: 6 Months after PMR visit
Change in Medication Access and Adherence Tool (MAAT) Score
The Medication Access and Adherence Tool (MAAT) will be used to assess change in medication adherence from Baseline to 6 Months. The MAAT is a tool that assesses participant-reported medication adherence. There are 5 questions with a score for each ranging from (1) not sure at all to (3) very sure. Possible scores range from 5 to 15, with higher scores indicating better medication adherence.
Measured: Baseline, 6 Months after PMR
Health-systems Alliance for Integrated Medication Management (HAIMM) Score after Personalized Medication Review
The Health-systems Alliance for Integrated Medication Management (HAIMM) survey will be used to assess participant-reported understanding and satisfaction after the Personalized Medication Review session with the study pharmacist. The HAIMM contains 10 questions. Scores range from (0) not applicable to (4) strongly agree for 9 questions, and (1) poor to (5) excellent for the tenth question. Possible scores range from 4 to 41, with higher scores indicating greater participant satisfaction.
Measured: After the PMR visit (up to 14 days after)
Health-systems Alliance for Integrated Medication Management (HAIMM) Score after Personalized Medication Review
The Health-systems Alliance for Integrated Medication Management (HAIMM) survey will be used to assess participant-reported understanding and satisfaction after the Personalized Medication Review session with the study pharmacist. The HAIMM contains 10 questions. Scores range from (0) not applicable to (4) strongly agree for 9 questions, and (1) poor to (5) excellent for the tenth question. Possible scores range from 4 to 41, with higher scores indicating greater participant satisfaction.
Measured: 6 Months after PMR visit
Change in Patient-Reported Outcomes Measurement Information System (PROMIS)
The Patient-Reported Outcomes Measurement Information System (PROMIS) survey measures health across 7 domains including cognition, depression, fatigue, pain, physical fitness, sleep and social roles. The Promis Preference (PROPr) Utility Score will be used to combine 7 PROMIS domains into a single health utility score. There are 14 questions and responses range from (1) Not at all to (5) Very much. Scores range from 14 to 70, with higher scores indicating better general health.
Measured: Baseline, 6 Months after PMR visit
Proportion of pharmacist recommendations were accepted
Proportion of pharmacist recommendations to address medication-related problems that were accepted by providers as assessed by EHR review.
Measured: 12 months after PMR visit
Frequency of Actionable Genotypes
Frequency of actionable genotypes (in the entire study population) based on report of a genotype-predicted phenotype. Actionable genotypes are defined as those with recommendations for a change in prescribing by a CPIC (Clinical Pharmacogenetics Implementation Consortium) guidelines or FDA recommendations.
Measured: At 12 months after PMR visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2024
- Study start15 Jan 2025
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PharmacogeneticsStudies of the same condition, open and under way.
- More trials run by University of PittsburghThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Pittsburgh
- Sponsor type
- University, hospital or other
- Collaborators
- University of Pittsburgh Medical Center
- Responsible party
- Principal investigator, Philip Empey, University of Pittsburgh
- Investigators
- Philip E Empey, PharmD, PhD, Principal investigator, University of Pittsburgh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06660264
- Sponsor's protocol ID
- STUDY23050142
- Acronym
- MyPGx
- Status last verified
- Sep 2026
- First submitted
- 23 Oct 2024
- Last updated
- 8 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No